Resolves

NYU Resolves Lawsuit with Jewish Students, Adopts New Anti-Discrimination Measures Amid Campus Tensions

by

NEW YORK — New York University recently reached a settlement with three Jewish students who accused the educational institution of failing to properly enforce its anti-discrimination policies amidst reports of antisemitic incidents on campus. This settlement, which agreed on July 8 for an undisclosed sum, concludes a lawsuit initiated in November 2023 by students Bella Ingber, Sabrina Maslavi, and Saul Tawil. The legal action spotlighted the university’s handling of discriminatory and harassing behavior directed at Jewish students, centering on antisemitic slurs and provocative chants that surfaced following the outbreak of conflict between Israel and Hamas … Read more

Merck Resolves Over 1,000 Zostavax Lawsuits Following Plaintiff Dismissals

by

Rahway, New Jersey — Merck & Co., a leading pharmaceutical company, has reached a significant legal milestone by resolving over a thousand lawsuits connected to its shingles vaccine, Zostavax. The cases were concluded following the plaintiffs’ decision to request dismissals, thus eliminating a batch of longstanding legal grievances against the drugmaker. Zostavax, designed to prevent shingles in older adults, was approved by the U.S. Food and Drug Administration in 2006. Marketed until its production ceased in 2020, it was the only shingles vaccine available in the U.S. for a decade before competitors like Shingrix emerged. … Read more

GSK Resolves Yet Another Zantac Legal Battle in California, Easing Concerns

by

San Francisco, California – Pharmaceutical company GlaxoSmithKline (GSK) has reached a settlement in yet another lawsuit regarding its popular heartburn medication, Zantac. The lawsuit was filed in California and alleged that the medication caused cancerous tumors in the plaintiff. GSK, based in the United Kingdom, has faced numerous lawsuits across the US concerning the potential link between Zantac and cancer. The settlement comes in the wake of recent studies that found the presence of a probable human carcinogen, NDMA, in ranitidine-based drugs like Zantac. The terms of the settlement were not disclosed, but GSK maintains … Read more